Table 4 Summary of the characteristics of studies that compare TUNA with other therapies
| Â | Author [reference number] | |||||||
|---|---|---|---|---|---|---|---|---|
| Â | Bruskewitz [50] | Roehrborn [51] | Chandrasekar [52] | Cimentepe [53] | Hill [54] | Schatzl [55,57] | Arai [56] | Minardi [58] |
Design | RCT | RCT | RCT | RCT | RCT | Prospective cohort | Prospective cohort | Prospective cohort |
No. patients | 121 | 121 | 156 | 59 | 121 | 95 | 204 | 212 |
TUNA [N. patients] | 65 | 65 | 76 | 26 | 65 | 15 | 51 | 24 |
Comparator [No. Patients] | TURP [56] | TURP [56] | TURP [76] | TURP [33] | TURP [56] | TURP [28] TUVP [17] VLAP [15] HIFU [20] | TURP [65] TUMT [40] ILC[48] | TURP [90] TUVP [13] ILC[71] WIT [13] |
Duration of symptoms | > 3months | > 3months | Not reported | Not reported | > 3months | Not reported | Not reported | Not reported |
Anesthesia | TUNA: Local TURP: General | TUNA: Local TURP: General | Not reported | Regional | TUNA: Local TURP: General | General/Regional | TUNA, ILC: Not reported TURP: Spinal TUMT: Local | TUNA-WIT:Local TUVP, ILC: Spinal TURP: General |
Variables assessed | Symptom, QoL, Qmax, PVR, prostatic size, adverse effects duration of procedure, hospital stay | Pdetat Qmax No. Abrams-Griffiths | Symptom, QoL, Qmax, adverse effects, hospital stay, re-treatment | Symptom, QoL, Qmax, PVR, sexual function, prostatic size, adverse effects, duration of procedure, hospital stay, re-treatment | Symptom, QoL, Qmax, PVR, adverse effects, hospital stay, re-treatment | Symptom, QoL, Qmax, PVR, adverse effects, hospital stay, re-treatment | Symptom, QoL, Qmax, PVR, sexual function, adverse effects. | Symptom, QoL, Qmax, PVR, Pdet at Qmax, prostatic size, adverse effects, duration, re-treatment |
Follow-up | 12 months | 6 months | 7 years | 18 months | 5 years | 6 weeks/24 m | 3 months | 24 months |
Randomization method specified | Yes | Yes | No | No | Â | Not applicable | Not applicable | Not applicable |
Inclusion/exclusion criteria specified | Yes | Yes | No | Yes | Â | Yes | Yes | Yes |
Concomitant treatment specified | Yes | Yes | No | Yes | Â | Yes | No | No |
Intention-to-treat analysis | Yes | Yes | Not reported | Not reported | Â | Yes | Not reported | Not reported |
Blind/Independent evaluation | Not reported | Not reported | Not reported | Not reported | Â | Not reported | Not reported | Not reported |
Losses | TUNA:9% TURP:16% | None | Not reported | None | TUNA>72% TURP > 60% | TUVP [4] VLAP [4] HIFU [4] TUNA [3] | TUNA [9] TURP [10] TUMT [6], ILC [6] | Not reported |